the aid library

LIST OPTIONS

Filter

2546

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer

Scherr, N.; R. Bieri, S.S. Thomas, et al. (2018) CC

Nat Commun 9, 5370 (2018). https://doi.org/10.1038/s41467-018-07804-8. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a neglected tropical skin disease that is most commonly found in children from West and Central Africa. Despite the severity of the infection, therapeutic options are... more

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Ghana

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr... more

Download (245)

View PDF (275)

Directrices de la OMS sobre el uso de antimicrobianos de importancia médica en animales destinados a la producción de alimento

World Health Organization WHO (2017) C_WHO

El abuso y el uso indebido de los antibióticos en animales y humanos están contribuyendo al aumento de la resistencia a estos fármacos. Algunos tipos de bacterias causantes de infecciones humanas graves ya son resistentes a la mayoría o a la totalidad de los tratamientos... more

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Uganda

Africa Center for Disease Control and Prevention (2023) CC

Download (1066)

View PDF (1559)

The BRAC Manoshi Approach to Initiating a Maternal, Neonatal and Child Health Project in Urban Slums with Social Mapping, Census Taking, and Community Engagement

Tapash Roy et al. (2015) C1

Accessed August 2015

Download (341)

View PDF (640)

Management of Children with Intellectual and Developmental Disability in an African Setting

Maroufou Jules Alao, Blaise Ayivi and Didier Lacombe (2012) CC

Chapter 2 in "Latest Findings in Intellectual and Developmental Disabilities Research" Edited by Üner Tan, ISBN 978-953-307-865-6, 404 pages, Publisher: InTech, Chapters published February 15, 2012 under CC BY 3.0 license | Intellectual and Developmental Disabilities presents reports on a wide rang... more

Download (242)

View PDF (355)

The immunological basis for immunization series: module 15: meningococcal disease, update 2020

World Health Organization WHO (2020) C_WHO

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Cameroon

Africa Center for Disease Control and Prevention (2023) CC

Download (256)

View PDF (255)

International instruments on the use of antimicrobials across the human, animal and plant sectors

the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO) (2020) C_WHO

The publication provides an overview and analysis of international instruments that set standards related to the use of antimicrobials across the human, animal and plant sectors, and their release into the environment. The purpose of the document is to identify existing instruments and standards in ... more

Download (435)

View PDF (567)

HEARTS D: diagnosis and management of type 2 diabetes

World Health Organization WHO (2020) C_WHO

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Gabon

Africa Center for Disease Control and Prevention (2023) CC

Download (320)

View PDF (463)

Hypertension Control Change Package

Centers for Disease Control and Prevention (CDC) (2020) C_CDC

second edition Included more self-measured blood pressure (SMBP)-focused content with tools and resources. Showcased more tools to find patients with potentially undiagnosed HTN. Added new strategies that focus on chronic kidney disease testing and identification.

Download (213)

View PDF (404)

Nodding syndrome

Scott F. Dowell, James J. Sejvar, Lul Riek, et al. CDC (2013) CC

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 19, No. 9, September 2013

Download (246)

View PDF (278)

Optimizing active case-finding for tuberculosis

World Health Organization. Regional Office for South-East Asia (2021) C_WHO

he WHO South-East Region in 2019 accounted for nearly a million missing TB patients from the estimated incidence. Active case-finding (ACF) or systematic screening for tuberculosis is an important tool to reach out to missing TB patients. When appropriately implemented, the activity is cost effectiv... more

Download (371)

View PDF (371)

Water, sanitation and hygiene in health care facilities: practical steps to achieve universal access to quality care

World Health Organization WHO; UNICEF (2019) C_WHO

Download (1025)

View PDF (1753)

Heat Waves, Floods And The Health Impacts Of Climate Change

World Health Organization WHO (2010) C_WHO

Training Workshop

Download (261)

View PDF (276)

Start Free, Stay Free, AIDS Free Final report on 2020 targets

UNAIDS; UNICEF; PEPFAR; WHO; Elizabeth Glaser Pediatric AIDS Foundation (2021) CC

Almost half (46%) of the world’s 1.7 million children living with HIV were not on treatment in 2020 and 150 000 children were newly infected with HIV, four times more than the 2020 target of 40 000

Download (272)

View PDF (385)

Giving Vitamin A and Deworming to Children Under Age Five: Course for Service Providers Facilitator’sGuide

Vitamin Angels Vitamin Angels (2016) C1

This Course for Service Providers on how to give Vitamin A Supplementation and Deworming (VAS+D) uses both a Learner’sGuide and a Facilitator’s Guide. The Learner’s Guide is designed for participants in the course who are healthcare workers or trainers learning to deliver vitamin A and Albenda... more

Download (158)

View PDF (181)

Guía de Práctica Clínica Enfermedad Pulmonar Obstructiva Crónica

Ministerio de Salud, Gobierno de Chile (2019) C1

Resumen Ejecutivo

Download (404)

View PDF (578)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more